Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
Status:
Withdrawn
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This will be an open label phase I/II prospective cohort study to determine the efficacy and
safety of CAMB for the treatment and prevention of cryptococcal infection.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Matinas BioPharma Nanotechnologies, Inc.
Collaborators:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute